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ELISA tests for dapsone and pyrimethamine and their
application in a malaria chemoprophylaxis programme
B. M. GREENWOOD,. A. M. GREENWOOD,2 A. K. BRADLEY,2 F. C. SHENTON,3
A. W. SMITH,2 R. W. SNOW,2 K. WILLIAMS,3 T. A. EGGELTE,4 H. HUIKESHOVEN,4 &
M. DE WIT5
Enzyme-linked immunosorbent assays (ELISAs) are describedfor determining levels
of dapsone and pyrimethamine in urine. Both assays have a sensitivity of about 20 ,ug/l
and are reproducible, but each produces some false positives. The problem of false
positive reactions was partially obviated by requiring positive results in both assays. In a
pilot study involving 50 children aged 3 months to 4 years who were given a single dose of
Maloprim (pyrimethamine + dapsone), 75% were positivefor dapsone 7 days after admin-
istration of the drug, while 25% were still positive 15 days after its administration. The
corresponding proportionsforpyrimethamine were 73% and 30%, respectively. Compari-
son of the results obtained in a larger chemoprophylaxis trial with those from the pilot
study indicated that the assays described could be used to investigate whether antimalarials
had been taken.
Use of chemoprophylaxis by the population of
areas where malaria is highly endemic is controversial.
In general, mass chemoprophylaxis is inadvisable;
however, it can be argued that malaria chemoprophy-
laxis should be given to pregnant women, especially
primigravidae, and young children. If chemo-
prophylaxis is employed it is important that as high a
degree of coverage as possible be achieved, since
otherwise drug resistance will probably be
encouraged.
Analysis of urine samples is the most reliable
method of assessing coverage in chemoprophylaxis
programmes; unfortunately, however, no simple and
reliable assays are available for the standard anti-
malarials in urine. Simple colorimetric assays for
chloroquine in urine have been reported (1, 2), but
gave a high rate of false positives in a study of young
Nigerian children' as well as a high rate of false
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negatives in children with high blood levels of chloro-
quine (3). No simple colorimetric assays for pyri-
methamine or proguanil are available and their assay
requires the use of complex biochemical tests or
chromatography. In 1979 Huikeshoven et al. (4)
described an enzyme-linked immunosorbent assay
(ELISA) for dapsone and subsequently showed that it
could be used to monitor treatment of leprosy
patients (5). Here, we describe a modification of this
assay, which together with a new ELISA test for pyri-
methamine, was used to monitor patient compliance
in a trial of malaria chemoprophllaxis using Malo-prim (pyrimethamine + dapsone).
MATERIALS AND METHODS
The study was carried out in the village of
Sarakunda, 20 km east of Farafenni, situated on the
north bank of the River Gambia. In October 1981 a
survey of the inhabitants of the village showed that its
population was 1161, of whom 152 were below 5
years of age. Tribally, 53% of the population were
Wollof and 43% Mandinka, while 4% belonged to
other smaller tribal groups. A register of births and
deaths has been maintained in the village since this
initial census.
b Burroughs Wellcome, Beckenham, England.
4740 -909-
910 B. M. GREENWOOD ET AL.
Pilot survey
In April 1982 a pilot study was undertaken in
Sarakunda in which Maloprim was administered to
50 children under 5 years of age (10 in each 1-year age
cohort). One quarter of a tablet of the drug (contain-
ing 6.25 mg pyrimethamine + 25 mg of dapsone) was
given to children aged 3-11 months and half a tablet
(containing 12.5 mg pyrimethamine +50 mg dap-
sone) to children aged 1-4 years. Administration of
the drug was supervised by one of the investigators.
Children were kept under observation for 30 minutes
after administration, and samples of urine and saliva
were collected 24 hours after the drug had been given
as well as on alternate days for the following 3 weeks.
Mothers collected the urine samples early on the
morning of the designated day and samples were
taken to Farafenni on the same day and stored at
-20 °C until assayed. At each sample collection,
mothers were questioned about any side-effects of the
drug, and children were examined for signs of
methaemoglobinaemia.
Main survey
In March 1983 a chemoprophylaxis trial was begun
in Sarakunda. Compounds in the village were
randomly assigned to one of the following treat-
ments: (1) Maloprim + folic acid; (2) Maloprim +
placebo; (3) chlorproguanil + folic acid; (4) chlor-
proguanil + placebo; (5) placebo + folic acid; and
(6) placebo + placebo. Maloprim was given in the
dose described above as specially formulated quarter-
strength tablets, while the dosage of chlorproguanil
was 20 mg and that of folic acid 5 mg. All children
under 5 years of age and all pregnant women were
included in the trial. Prophylaxis was given at fort-
nightly sessions held in the village community centre
by Medical Research Council field staff. Records of
drug administration were kept using a system de-
signed for use by illiterate village health workers (6).
Samples of urine for assays were obtained from all
children who attended a monthly clinic held in the
village by a project physician, and further samples
were obtained in November 1984 during a cross-
sectional survey of all cohort children.The nature and
date of the last drug administration were recorded.
Samples of urine from controls were obtained in
November 1984 from children in neighbouring
hamlets where no drugs had been administered.
Preparation of samples
Samples of urine and saliva were stored at - 20 °C
until tested. Before being assayed, each sample was
tested with phenol red indicator and adjusted to
approximately pH 7.0 by addition of either a 10%
solution of ammonium hydroxide or 0.1 mol/l
hydrochloric acid. A 1:10 dilution of samples of urine
or saliva in phosphate-buffered saline (PBS)/Tween
(0.0507o Tween-20 in PBS (v/v), pH 7.3) produced
the optimum discrimination between positive and
neg'ative samples.
Standard solutions
Standard solutions of dapsone and pyrimethamine
(pH 7.0) covering the concentration range 0.5-
1000 jsg/l were prepared in aliquots of urine pooled
from individuals who had never taken either drug.
Part of the urine pool was also used to provide a
blank. The standard solutions were preserved by
addition of thiomersal to a concentration of 0.02%7.
(w/v) and were diluted 1:10 in PBS/Tween before
use.
Preparation of antisera to dapsone and pyrimeth-
amine and enzyme conjugates
Dapsone was conjugated to horseshoe crab haemo-
cyanin, and antiserum to the conjugate was raised by
immunizing rabbits with conjugate plus Freund's
adjuvant (4). Antiserum to a pyrimethamine/
haemocyanin conjugate was prepared similarly, and
both antisera were conjugated with peroxidase (4).
ELISA test for dapsone
Nunc Immuno 1 microtitre trays were used for the
ELISA test. Initially, 100 1l of a solution of dapsone
antiserum in carbonate buffer (pH 9.6) was added to
each well and the trays were incubated at 37 °C for 12
hours (Fig. 1). The trays were then washed ( x 6) with
PBS/Tween, and 75 jd of either standard or test
sample diluted 1:10 in PBS/Tween was added
followed by 25 1l of enzyme-dapsone conjugate in
PBS/Tween supplemented with 1O0o horse serum.
After incubation for 2 hours at 37 IC, the trays were
washed (x6) and 100,ul solution of ABTS (2,2'-
azino-di-(3-ethyl)benzothiazolinesulfonic acid) in
hydrogen peroxide was added to each well. This sol-
ution of 5 mg ABTS in 10 ml of 0.1 mol/l phosphate-
citrate buffer (pH 4.0) + 18 ul of 107o hydrogen perox-
ide was prepared immediately before use. After a
further 2 hours' incubation at room temperature, the
contents of each well were analysed colorimetrically
at A = 405 nm using a Titertek Multiskan instrument.C
Samples were analysed in duplicate and the mean
absorbance determined. The absorbance of the test
samples was compared with that of blanks from the
urine pool and the proportional reduction in absor-
bance determined. An inhibition of the colour
From Flow Laboratories, Irvine, Scotland.
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reaction of about 200/ could be detected with the
naked eye, and this level was therefore taken as a
convenient cut-off for negative and positive samples.
For dapsone antiserum the optimum concentration
of IgG for coating was 6.25 mg in 100 Al coating
buffer, while for the enzyme-dapsone conjugate the
optimum dilution was 1:500. These concentrations
were used in all subsequent assays.
ELISA test for pyrimethamine
For the pyrimethamine assay, in contrast to the
dapsone assay, antigen was bound to the microtitre
tray (Fig. 1). Optimum results were obtained with
Dynatech M129 A microtitre trays. Initially, 100 1l
of pyrimethamine-haemocyanin conjugate in car-
bonate buffer (pH 9.6) was added to each well of the
trays, which were then incubated for 1 hour at 30 'C.
After washing (x 6) in PBS/Tween, 75 Al of test
sample (or standard) diluted 1:10 in PBS/Tween was
added to each well followed by 25 Al of anti-pyri-
methamine immunoglobulin conjugated with perox-
idase. After incubation for 2 hours at 37 'C, trays
were washed (x 6) and 100 yd of ABTS/ hydrogen
peroxide solution added to each well. After incu-
bation for a further 2 hours at room temperature, the
absorbance of the solutions was determined colori-
metrically at X = 405 nm. Positive and negative
responses were defined as described for the dapsone
assay. The optimum concentration of pyrimeth-
amine-haemocyanin conjugate was 2.5 mg/l buffer,
and that of the enzyme conjugated anti-pyrimeth-
amine antiserum 1:200 in PBS/Tween supplemented
with 1007 horse serum. These concentrations were
used in all subsequent assays.
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Fig. 1. Schematic representation of the ELISA tests
for dapsone and pyrimethamine (anti-DDS = dapsone
antiserum).
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Fig. 2. Inhibition of colour reaction in dapsone (0) and
pyrimethamine (*) ELISA tests by various concen-
trations of dapsone and pyrimethamine in normal urine.
Plots show the mean + standard deviation of 35
observations.
RESULTS
Sensitivity, specificity, and reproducibility
The lower limit of detection for dapsone and pyri-
methamine in urine was approximately 20 Ag/l and
the reproducibility of both assays for standard sol-
utions was good (Fig. 2). In order to determine the
reproducibility of the assays for test solutions, the
following samples of urine were assayed five times
each: 10 samples that were definitely positive ( > 4001o
inhibition), 10 that were weakly positive (20-4007o
inhibition), and 10 that were negative (< 2007o inhibi-
tion). All the samples that produced > 4007o inhibition
were positive in each of the five dapsone assays. Nine
were positive in each of the pyrimethamine assays,
while the remaining sample was negative in only one
of the five pyrimethamine assays. Similar results were
obtained with the negative samples: nine were
negative in each assay, while one was positive on one
occasion in each assay. More variable results were
obtained among the weakly positive urines, and nine
and eight samples, respectively, were negative on at
least one occasion in the pyrimethamine and dapsone
assays.
Samples of urine from 45 children were obtained
approximately 24 hours after administration of a
quarter or half tablet of Maloprim. A positive
dapsone assay (> 2007o inhibition) was exhibited by 44
samples (98 7o), while 42 samples (93 70) were positive
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for pyrimethamine. Forty-two samples (93%) were
also positive in both assays. Urine samples were also
assayed from 247 children who lived in 27 hamlets in
the Farafenni area where no drug prophylaxis had
taken place and where access to drugs was limited: 23
samples (9.5%) were positive for dapsone and 11
(4.5%) for pyrimethamine. Twelve ofthe samples that
were positive for dapsone were from children who
lived in a cluster of five adjacent hamlets. Only seven
samples (2.81o) were positive in both assays. Urine
from children who had not been prescribed anti-
malarials remained positive in the assays after samples
were treated with phosphate-citrate buffer (pH 2) or
boiled for 2 minutes. The combined results of the
dapsone and pyrimethamine assays were therefore
more specific than the results of either assay alone. If
it is assumed that all the samples of urine obtained 24
hours after administration of Maloprim contained
dapsone and pyrimethamine (some children may have
vomited after the observation period), for the
combined assays the sensitivity and specificity were
93% and 97%0, respectively.
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Pilot study
Samples of urine were collected from 45 children
aged less than 4 years over a period of 19 days
following administration of Maloprim (quarter tablet
for 9 children aged 3-11 months and a half tablet for
36 children aged 1-4 years). The mean inhibition of
absorbance at X = 405 nm of these samples compared
to that of normal urine is plotted in Fig. 3 and 4
against the time elapsed after administration of the
drug. The proportion of children whose urine
produced > 20% inhibition in the dapsone and pyri-
methamine assays (equivalent to about 50 ug/l of
dapsone or 20 ytg/l of pyrimethamine) as a function
of the number of days after treatment is shown in Fig.
5. Urinary levels of dapsone and pyrimethamine were
generally higher for children aged 1-4 years who had
been given a half tablet of Maloprim than for
children aged 3-11 months given a quarter tablet.
Dapsone levels in urine fell more rapidly than pyri-
methamine levels.
Relative to phosphate-buffered saline, samples of
saliva collected from 49 children immediately before
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Fig. 3. Inhibition of colour reaction in the dapsone ELISA
test by post-treatment samples of urine from 9 children
aged < 1 year ( 0 ) given a quarter tablet of Maloprim and
from 36 children aged 1-4 years ( @ ) given a half tablet
of the drug.
Fig. 4. Inhibition of colour reaction in the pyrimethamine
ELISA test by post-treatment samples of urine from 9
children aged < 1 year ( 0 ) given a quarter tablet of
Maloprim and from 36 children aged 1-4 years (*)
given a half tablet of the drug.
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Fig. 5. Proportion of urine samples from 9 children aged
< 1 year given a quarter tablet of Maloprim and from 36
children aged 1-4 years given a half tablet that were
positive for dapsone ( ), pyrimethamine (B), or
dapsone + pyrimethamine (D) at various times after
treatment.
and again 24 hours after Maloprim had been adminis-
tered were strongly inhibitory in the dapsone ELISA
test (mean inhibition before drug administration,
-50.7%; after administration, -59,2%). This degree
of inhibition was not observed in the ELISA test for
pyrimethamine, where a mean value of + 1.9% was
obtained before administration of Maloprim and
- 4.6%7 was observed 24 hours after the drug had
been given. An increase in inhibition after drug
administration occurred with both assays, but the
difference was statistically significant only for pyri-
methamine (P<0.01). For both assays a wide degree
of overlap occurred between pre- and post-drug
administration values.
Main study
Samples of urine from children who attended a
monthly clinic over a 2-year period and from children
examined in a cross-sectional survey were assayed for
dapsone and pyrimethamine. No significant differ-
ences were found between clinic and survey samples
and results were therefore pooled. Table 1 shows the
proportion of positive assays related to the period
elapsed from the last drug administration recorded
on the child's health card together with the
corresponding data from the pilot study. The results
of both studies are comparable for 2 weeks after the
last drug administration. However, in the third week
significantly more children examined during routine
surveillance were positive for dapsone, pyri-
methamine, and both assays combined than were
children covered in the pilot study (P< 0.001,
P< 0.01, and P< 0.05, respectively). Analysis of
these data indicated that samples from children in the
main study had been collected 2 days earlier, on
average, in the third week than those in the pilot
survey. If the data are compared at 2-day, rather than
weekly intervals, there is no significant difference
between the results of the main and pilot studies
(Mantel-Haenszel test; P> 0. 1).
Table 2 shows the results of the assays of urine
from Sarakunda children who received either chlor-
proguanil or placebo and those from children living
in hamlets where no known chemoprophylaxis
occurred. A slightly higher fraction of samples were
positive in both dapsone and pyrimethamine assays
for the Sarakunda children than for the controls, but
the difference was only statistically significant
(P<0.01) if the results of the pyrimethamine assays
of Sarakunda children who received placebo were
compared with controls. There were no significant
Table 1. Results of ELISA tests for dapsone and pyrimethamine in urine according to the period elapsed after
administration of Maloprim in the main study and pilot surveys
Proportion positive in ELISA test
Mean number of days
after administration Dapsone Pyrimethamine Dapsone + pyrimethamine
Pilot survey Main study Pilot survey Main study Pilot survey Main study Pilot survey Main study
3.0±1.7 3.1 ±1.6 119/135 59/69 114/129 47/60 99/129 41/60
(88) ° (86) (88) (78) (77) (68)
10.0±2.2 8.6±1.5 71/179 20/27 101/174 8/15 49/174 5/15
(40) (74) (58) (53) (28) (33)
16.9± 1.6 14.9± 1.6 17/127 42/101 34/128 36/83 8/127 13/83
(13) (42) (27) (43) (6) (16)
a Figures in parentheses are percentages.
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Table 2. Results of ELISA tests for dapsone and pyrimethamine in urine from children administered chlorproguanil
or placebo and from controls
Proportion positive in ELISA test
Group Dapsone Pyrimethamine Dapsone + pyrimethamine
Main study:
Placebo 24/183 (13)a 21/175 (12) 9/175 (5)
Chlorproguanil 24/173 (14) 14/159 (9) 7/159 (4)
Controls 23/247 (9) 11/247 (5) 7/247 (3)
a Figures in parentheses are percentages.
differences when the results of both the dapsone and
pyrimethamine assays were combined.
DISCUSSION
The dapsone and pyrimethamine assays were sensi-
tive, reproducible, and easy to perform. Consistent
results were obtained for samples of urine that were
strongly positive or negative. In contrast, less repro-
ducible results were obtained with samples that were
weakly positive (20-400o inhibition), and the speci-
ficity of the assay would have been increased had
40Go instead of 20%o inhibition been used as the
positive cut-off level; however, a 40%o inhibition level
would have lowered the sensitivity of the assay.
Fortunately, only about 1507o of all positive reactions
were weak, and hence any inconsistencies in urine
assays should not have any marked overall effect on
the results.
Use of the assays to monitor the administration of
Maloprim was problematic since about 5-100o of
urine samples from children who were not known to
have received dapsone or pyrimethamine were posi-
tive in one or other of the assays for these substances.
Many of these samples were strongly positive and
remained so even after they had been diluted to a
concentration of 1:100 or when a higher level of
inhibition was used as the criterion for a positive
test.
In the Gambia dapsone is occasionally given by
unqualified medical practitioners for conditions
other than leprosy, while pyrimethamine is some-
times available in pharmacies. However, it is unlikely
that either these or related drugs were available in the
isolated hamlets around Sarakunda, and investi-
gations in hamlets where several positive dapsone
assays were found failed to reveal any source of this
drug. It is therefore likely that these reactions were
false positives caused perhaps by reaction between a
dietary metabolic product and the antisera used in the
ELISA tests; this possibility is being investigated
further. Urine from children who had received
Maloprim was usually positive in both the dapsone
and pyrimethamine assays, while urine from children
who had probably not received either of these drugs
was normally positive in only one assay. Use as
selection criterion of a positive result in both assays
discriminated between true and false positives and
gave a test with satisfactory sensitivity and specificity
(93%o and 9707o, respectively).
Both dapsone and pyrimethamine are excreted in
saliva (7), and since its collection could be directly
supervised by the investigators both saliva and urine
were assayed in the pilot study. Surprisingly, all
samples of saliva collected prior to drug adminis-
tration were strongly positive in the dapsone assay,
which could therefore not be used to monitor
Maloprim compliance. This may have been caused by
a cross-reaction with a substance normally present in
saliva. In the pyrimethamine ELISA test there was a
small but statistically significant difference between
the mean inhibition level in assays of saliva collected
before and after administration of Maloprim, but the
large spread of results precluded use of this assay.
In order to validate the results of the ELISA tests,
samples of urine were collected from a group of
children under 5 years of age who had been given a
quarter or a half tablet of Maloprim under direct
surveillance. As expected from their respective half-
lives in plasma (8), dapsone disappeared from the
urine more rapidly than pyrimethamine, but 400/o of
samples collected during the second week after
administration of Maloprim were still positive in the
dapsone ELISA test. Dapsone was therefore prob-
ably present in the plasma of these children in
sufficient concentrations to produce a synergic effect
with pyrimethamine for at least 1 week after drug
administration.
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The ELISA tests were also used to monitor com-
pliance in a larger chemoprophylaxis study involving
six drug regimens. Comparison of the results of urine
assays from children who should have received
chlorproguanil or placebo with those from control
children confirmed that the former children had not
received Maloprim. Also, the results of assays of
urine from children designated to receive Maloprim
were closely similar, for the first two weeks after
administration, to those from children in the pilot
study who received Maloprim under surveillance.
Samples obtained from study children during the
third week after drug administration exhibited a
higher proportion of positives than comparable
samples from children in the pilot study; however,
this variation largely arose because of differences in
the collection times for the two groups, almost all
samples from children in the test group having been
obtained during the early part of the third week,
while those from the pilot study were collected more
evenly throughout this week. Nevertheless, the study
shows that the ELISA tests for dapsone and
pyrimethamine, despite the problem posed by false
positive reactions, can provide useful information
about the efficacy of a malaria chemoprophylaxis
programme.
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RESUME
LES tPREUVES ELISA POUR LA RECHERCHE ET LE DOSAGE DE LA DAPSONE ET DE LA PYRIMMETHAMINE,
ET LEUR UTILISATION DANS LES PROGRAMMES DE CHIMIOPROPHYLAXIE DU PALUDISME
Dans le present article sont decrites des methodes de
titrage immunoenzymatique (ELISA) pour la dapsone et la
pyrimethamine, et leur application a l'etude de l'observance
du traitement par un antipaludeen, le Maloprim (pyri-
methamine + dapsone). Les 2 titrages reposent sur l'inhi-
bition de la reaction coloree provoquee par l'action de la
peroxydase sur une solution d'acide azino-2,2'bis(ethyl-3)
benzothiazoline sulfonique dans l'eau oxygenee. Une
inhibition de 20% de la reaction coloree est decelable a l'oeil
nu et c'est ce seuil qui a ete utilise pour distinguer les
echantillons positifs et negatifs. La limite de detection est
de 20 1&g/l de dapsone ou de pyrimethamine dans l'urine
normale, et avec des echantillons negatifs ou fortement
positifs on obtient une bonne reproductibilite; les resultats
varient davantage avec les echantillons de teneur moyenne.
Dans une etude pilote, des 6chantillons d'urine ont 6te
pr6lev6s chez 45 enfants ages de 3 mois a 4 ans, 24 heures
environ apres l'administration d'un quart ou d'un demi-
comprime de Maloprim. En ELISA, 44 echantillons (98%)
se sont reveles positifs pour la dapsone, 42 (93%) pour la
pyrimethamine et 42 (93%) pour les deux m6dicaments. Des
titrages ont egalement et pratiques sur des echantillons
d'urine preleves chez 247 enfants habitant des hameaux oui
aucune chimioprophylaxie n'avait ete administr&e: 23
(9,5%o) se sont montres positifs pour la dapsone et 11 (4,5%qo)
pour la pyrimethamine). Sept echantillons seulement (soit
2,8%o) etaient positifs dans les deux epreuves. La sensibilite
et la specificite des deux epreuves associees sont par con-
sequent de 93%0 et 97% respectivement. Les "faux positifs"
n'ont pas ete supprimes en chauffant ou en acidifiant l'urine
et ils font l'objet d'une investigation plus approfondie. Des
echantillons d'urine ont et recueillis un jour sur deux
pendant trois semaines chez 45 enfants ages de 3 mois a 4 ans
apres administration d'un quart ou d'un demi-comprime de
Maloprim. Les echantillons se sont montres positifs pour la
dapsone chez 75%o des enfants 7 jours apres la prise du medi-
cament, et au bout de 15 jours 25% etaient encore positifs.
En ce qui concerne la pyrimethamine, les chiffres correspon-
dants etaient de 7301o et 30%.
Les resultats fournis par cette enquete pilote ont et
employes pour surveiller l'observance dans un essai chimio-
prophylactique comportant six schemas therapeutiques. Les
echantillons d'urine ont et recueillis chez les enfants
conduits dans les dispensaires pour les visites systematiques
ainsi qu'au cours d'une enquete transversale. En comparant
les resultats obtenus avec ceux de l'enquete pilote, il ressort
que les medicaments ont 06 administres conformement a ce
que les meres avaient indique.
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